The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma

SIMPLE SUMMARY: Advances in melanoma treatment include v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors that target the predominant oncogenic mutation found in malignant melanoma. Despite initial success of the BRAF inhibitor (BRAFi) therapies, resistance and secondary cancer often oc...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Elizabeth L., Hu, Jiayi J., Niedernhofer, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125319/
https://www.ncbi.nlm.nih.gov/pubmed/34066966
http://dx.doi.org/10.3390/cancers13092241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125319/
https://www.ncbi.nlm.nih.gov/pubmed/34066966
http://dx.doi.org/10.3390/cancers13092241

Ejemplares similares